Exchange eases biotech listings
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE STOCK EXCHANGE is planning to relax listing regulations for biotechnology and other research-based companies, following intense lobbying from the City and venture capital groups, writes Neil Thapar.
Formal proposals are understood to be under discussion by the Exchange's quotations committee and are likely to be announced within the next few weeks.
The present regulations, brought in last December, allow biotechnology firms with at least two drugs in pre-clinical trial to float on the stock market even if they do not have a three-year trading record - a pre-requisite for other types of company that are seeking a public quote.
But directors of biotechnology firms cannot sell shares in their companies for at least two years after flotation and must show three years' employment with their firms.
However, it is understood that these conditions will be relaxed, enabling a broader range of research-based companies to join the market.
Sources suggest firms engaged in the development of veterinary drugs or diagnostic products for decontaminating foodstuffs will be brought under the scope of the new rules.
The changes are being considered after heavy lobbying from both stockbrokers and venture capital firms keen to float more scientific research companies.
Dozens more companies may become eligible for listing if the expected changes are approved.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments